Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

Impact · against what's priced in

The article provides no new catalysts for DaVita, as the positive drivers mentioned—IKC growth and raised guidance—are already reflected in the stock's recent 55.8% rally. The mentioned risks regarding commercial payer-mix pressures align with the market's current conservative valuation.

DVA+0.00

Already priced in

The price assumes

A 3.2% annual revenue growth rate over the next decade

The article's mention of strong execution in the IKC platform and higher guidance explains the stock's 55.8% year-to-date rally, but it does not provide evidence of the commercial mix recovery that the market is currently not paying for.

What DVA's price assumes · Sep 4

• earnings
• healthcare
• guidance
• DVA
• dialysis
• kidney care
• medical technology

Search tags